瑞舒伐他汀对老年冠心病患者动脉硬化、炎性反应与同型半胱氨酸的影响研究
|
摘要
目的探讨瑞舒伐他汀对老年冠心病患者动脉硬化、炎性反应与同型半胱氨酸的影响。方法选取我院(2017年1月至2018年1月)收治的90例冠心病患者,根据不同治疗入院序号分为两组,两组患者均给予控制血糖、血压和低盐低脂饮食、冠心病健康宣教以及适量运动等常规治疗,对照组(n=45)给予阿托伐他汀钙片治疗,观察组(n=45)给予瑞舒伐他汀治疗,对比两组患者治疗前后血脂水平和同型半胱氨酸(Hcy)、炎性反应、动脉硬化程度和不良事件发生率。结果两组患者HDL-C、LDL-C、TG、TC水平对比差异明显,具有统计学意义(P<0.05)。两组患者Hcy、TNF-α、hs-CRP水平对比差异明显,具有统计学意义(P<0.05)。两组患者FMD、IMT对比差异明显,具有统计学意义(P<0.05)。两组患者心血管不良事件发生率对比差异不明显,无统计学意义(P>0.05)。结论瑞舒伐他汀对老年冠心病患者不仅有较好的治疗效果,还具有较高的安全性。
Objective To investigate the effects of rosuvastatin on atherosclerosis,inflammation and homocysteine in elderly patients with coronary heart disease.Method Ninety patients with coronary heart disease admitted to our hospital from January 2017 to January 2018 were divided into two groups according to the number of admission.The two groups were given routine treatment such as controlling blood sugar,blood pressure,low salt and low fat diet,health education of coronary heart disease and moderate exercise.The control group(n=45) was given atorvastatin calcium tablets and the observation group(n=45) was given rosuvastatin.The levels of blood lipid and homocysteine(Hcy),inflammation,degree of arteriosclerosis and incidence of adverse events were compared between the two groups before and after treatment.Results:There were significant differences in HDL-C,LDL-C,TG and TC levels between the two groups(P<0.05).The levels of Hcy,TNF-α and hs-CRP were significantly different between the two groups(P<0.05).There were significant differences in FMD and IMT between the two groups(P<0.05).There was no significant difference in the incidence of cardiovascular adverse events between the two groups(P>0.05).Conclusion Rosuvastatin not only has better therapeutic effect on elderly patients with coronary heart disease,but also has higher safety.
Objective To investigate the effects of rosuvastatin on atherosclerosis,inflammation and homocysteine in elderly patients with coronary heart disease.Method Ninety patients with coronary heart disease admitted to our hospital from January 2017 to January 2018 were divided into two groups according to the number of admission.The two groups were given routine treatment such as controlling blood sugar,blood pressure,low salt and low fat diet,health education of coronary heart disease and moderate exercise.The control group(n=45) was given atorvastatin calcium tablets and the observation group(n=45) was given rosuvastatin.The levels of blood lipid and homocysteine(Hcy),inflammation,degree of arteriosclerosis and incidence of adverse events were compared between the two groups before and after treatment.Results:There were significant differences in HDL-C,LDL-C,TG and TC levels between the two groups(P<0.05).The levels of Hcy,TNF-α and hs-CRP were significantly different between the two groups(P<0.05).There were significant differences in FMD and IMT between the two groups(P<0.05).There was no significant difference in the incidence of cardiovascular adverse events between the two groups(P>0.05).Conclusion Rosuvastatin not only has better therapeutic effect on elderly patients with coronary heart disease,but also has higher safety.
引文
[1]杨添宝,王洪.瑞舒伐他汀对急性冠脉综合征患者超敏C反应蛋白及同型半胱氨酸水平的影响[J].中国实用医药,2018,13(33):125-127.
[2]陈梅,郭明升,武华,等.阿托伐他汀和瑞舒伐他汀对非糖尿病脑梗死二级预防患者血糖的影响[J].河北医科大学学报,2019,40(1):16-19.
[3]梁科,许峰,赵伟.不同剂量瑞舒伐他汀对外周动脉粥样硬化症患者踝肱指数及超敏C反应蛋白的影响[J].中国医院用药评价与分析,2018,18(12):1624-1626.
[4]余波,张韶英,聂斌.瑞舒伐他汀对动脉钙化的疗效及对骨保护素/核因子κB受体活化因子配体的影响[J].中国老年学杂志,2018,38(24):5898-5900.
[5]孟庐松,弓晋灵,武文,等.参麦注射液联合瑞舒伐他汀对心力衰竭患者炎性因子及心功能的影响[J].心脑血管病防治,2018,18(6):477-479.
[6]刘琼,张欣,许宇文,朱琰.瑞舒伐他汀对老年冠心病病人动脉硬化、炎性反应及同型半胱氨酸的影响[J].实用老年医学,2018,32(12):1138-1141.
[7]高鹏,王萍萍.瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效对比分析[J].中国医药指南,2018,16(33):96-97.
[8]董少元,屈艳玲.瑞舒伐他汀与阿托伐他汀治疗冠状动脉斑块疗效及调脂作用观察[J].中国药物与临床,2018,18(12):2189-2190.
[9]戴开圣.银杏达莫联合瑞舒伐他汀治疗不稳定性心绞痛的临床观察[J].中国处方药,2018,16(12):67-68.
[10]陈建慧,曾辉平,石泉.瑞舒伐他汀联合麝香保心丸对冠心病合并2型糖尿病患者疗效的影响[J].当代医学,2018,24(34):84-86.
[11]连永红.不同剂量瑞舒伐他汀对冠心病介入术后患者的临床疗效[J].河南医学研究,2018,27(21):3895-3897.
[12]刁春丽.瑞舒伐他汀联合硫酸氢氯吡格雷对冠心病患者心功能和血清炎性因子水平的影响[J].河南医学研究,2018,27(21):3935-3936.
[13]张志芳.不同剂量瑞舒伐他汀治疗对老年冠心病合并心力衰竭患者心功能的影响[J].实用临床医药杂志,2018,22(23):22-25.
[2]陈梅,郭明升,武华,等.阿托伐他汀和瑞舒伐他汀对非糖尿病脑梗死二级预防患者血糖的影响[J].河北医科大学学报,2019,40(1):16-19.
[3]梁科,许峰,赵伟.不同剂量瑞舒伐他汀对外周动脉粥样硬化症患者踝肱指数及超敏C反应蛋白的影响[J].中国医院用药评价与分析,2018,18(12):1624-1626.
[4]余波,张韶英,聂斌.瑞舒伐他汀对动脉钙化的疗效及对骨保护素/核因子κB受体活化因子配体的影响[J].中国老年学杂志,2018,38(24):5898-5900.
[5]孟庐松,弓晋灵,武文,等.参麦注射液联合瑞舒伐他汀对心力衰竭患者炎性因子及心功能的影响[J].心脑血管病防治,2018,18(6):477-479.
[6]刘琼,张欣,许宇文,朱琰.瑞舒伐他汀对老年冠心病病人动脉硬化、炎性反应及同型半胱氨酸的影响[J].实用老年医学,2018,32(12):1138-1141.
[7]高鹏,王萍萍.瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效对比分析[J].中国医药指南,2018,16(33):96-97.
[8]董少元,屈艳玲.瑞舒伐他汀与阿托伐他汀治疗冠状动脉斑块疗效及调脂作用观察[J].中国药物与临床,2018,18(12):2189-2190.
[9]戴开圣.银杏达莫联合瑞舒伐他汀治疗不稳定性心绞痛的临床观察[J].中国处方药,2018,16(12):67-68.
[10]陈建慧,曾辉平,石泉.瑞舒伐他汀联合麝香保心丸对冠心病合并2型糖尿病患者疗效的影响[J].当代医学,2018,24(34):84-86.
[11]连永红.不同剂量瑞舒伐他汀对冠心病介入术后患者的临床疗效[J].河南医学研究,2018,27(21):3895-3897.
[12]刁春丽.瑞舒伐他汀联合硫酸氢氯吡格雷对冠心病患者心功能和血清炎性因子水平的影响[J].河南医学研究,2018,27(21):3935-3936.
[13]张志芳.不同剂量瑞舒伐他汀治疗对老年冠心病合并心力衰竭患者心功能的影响[J].实用临床医药杂志,2018,22(23):22-25.